Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Sam L. Barker acquired 1,000 shares of the firm’s stock in a transaction dated Friday, September 15th. The stock was purchased at an average cost of $12.50 per share, with a total value of $12,500.00. Following the completion of the acquisition, the director now directly owns 25,623 shares of the company’s stock, valued at approximately $320,287.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) traded down 0.16% on Thursday, hitting $12.61. The stock had a trading volume of 40,163 shares. The firm’s market cap is $1.33 billion. The company’s 50-day moving average price is $14.41 and its 200 day moving average price is $15.27. Lexicon Pharmaceuticals, Inc. has a 12-month low of $11.80 and a 12-month high of $19.62.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.12. The business had revenue of $12.00 million during the quarter, compared to analyst estimates of $18.34 million. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The company’s revenue was down 40.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.37) earnings per share. On average, equities research analysts forecast that Lexicon Pharmaceuticals, Inc. will post ($1.45) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Lexicon Pharmaceuticals, Inc. (LXRX) Director Purchases $12,500.00 in Stock” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://stocknewstimes.com/2017/09/21/lexicon-pharmaceuticals-inc-lxrx-director-purchases-12500-00-in-stock.html.
LXRX has been the subject of several recent research reports. Zacks Investment Research raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Wedbush reissued an “ourperform” rating and issued a $39.00 target price on shares of Lexicon Pharmaceuticals in a report on Monday, August 7th. BidaskClub downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. Finally, ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $27.00.
Institutional investors have recently made changes to their positions in the company. State of Wisconsin Investment Board acquired a new stake in shares of Lexicon Pharmaceuticals in the second quarter valued at $510,000. Highbridge Capital Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals in the first quarter valued at $7,813,000. Pictet Asset Management Ltd. lifted its holdings in shares of Lexicon Pharmaceuticals by 10.4% in the second quarter. Pictet Asset Management Ltd. now owns 67,950 shares of the biopharmaceutical company’s stock valued at $941,000 after buying an additional 6,400 shares during the period. Sector Gamma AS acquired a new stake in shares of Lexicon Pharmaceuticals in the first quarter valued at $4,765,000. Finally, First Mercantile Trust Co. lifted its holdings in shares of Lexicon Pharmaceuticals by 11.2% in the second quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 1,227 shares during the period.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.